Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial
- 15 October 2014
- journal article
- research article
- Published by Wiley in British Journal of Dermatology
- Vol. 171 (5), 1215-1219
- https://doi.org/10.1111/bjd.13065
Abstract
In patients with moderate-to-severe psoriasis, health-related quality of life (HRQOL) has been shown to improve in parallel with improvement in disease severity. To evaluate the role of pruritus (itch) in mediating the relationship between improvements in disease severity and HRQOL. Data from a phase 2 clinical trial, in which 142 patients with moderate-to-severe plaque psoriasis received ixekizumab or placebo, were used for this posthoc analysis. Relationships between improvement in Psoriasis Area and Severity Index (PASI), Itch Visual Analogue Scale (VAS) and Dermatology Life Quality Index (DLQI), as well as in individual DLQI domains (symptoms and feelings, treatment, work and school, daily activities, leisure, and personal relationships) from baseline to week 16 were determined. Multiple hierarchical linear regressions and Sobel tests were conducted to evaluate the results. Improvement in PASI was highly correlated with pruritus improvement and improvements in DLQI total and domain scores at week 16 (P < 0·01). Multiple hierarchical linear regression analyses showed a statistically significant (P < 0·01) association between improvement in pruritus and improvement in DLQI total score and each of the six DLQI domain scores after adjusting for improvement in PASI. Sobel tests indicated that pruritus had a significant mediation effect (P < 0·05) on the association of PASI improvement with improvement in DLQI total score and all domains except the personal relationships score. Pruritus appears to be an important mediator of the association between improvements in disease severity and HRQOL in patients with moderate-to-severe psoriasis.Funding Information
- Eli Lilly and Company
This publication has 14 references indexed in Scilit:
- Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapiesJournal of the European Academy of Dermatology and Venereology, 2013
- Itch Severity and Quality of Life in Patients with Pruritus: Preliminary Validity of a Danish Adaptation of the Itch Severity ScaleActa Dermato-Venereologica, 2012
- Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque PsoriasisThe New England Journal of Medicine, 2012
- Effect size measures for mediation models: Quantitative strategies for communicating indirect effects.Psychological Methods, 2011
- The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical resultsBritish Journal of Dermatology, 2008
- Relationship between Clinical Response to Therapy and Health-Related Quality of Life Outcomes in Patients with Moderate to Severe Plaque PsoriasisDermatology, 2008
- Affective and Sensory Dimensions of Pruritus Severity: Associations with Psychological Symptoms and Quality of Life in Psoriasis PatientsActa Dermato-Venereologica, 2008
- Psychosomatic cofactors and psychiatric comorbidity in patients with chronic itchClinical and Experimental Dermatology, 2006
- Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global AssessmentJournal of the American Academy of Dermatology, 2004
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994